Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Mark A. Schroeder, MD, H. Jean Khoury, MD FACP, Madan Jagasia, MD MS, Haris Ali, MD, Gary J. Schiller, MD, Michael Arbushites, Patricia Delaite, Ying Yan, Kathleen Rhein, Miguel-Angel Perales, MD, Yi-Bin Chen, MD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 390.

https://doi.org/10.1182/blood.V128.22.390.390

Published: 2016

Journal Articles

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Vamsi Kota, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Jeffrey H. Lipton, MD PhD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Fiona An, MD, Eric Leip, PhD, Rocco J. Crescenzo, DO, FACOI, Mabel Woloj, PhD, Mark Shapiro, MD PhD, H. Jean Khoury, MD FACP

Blood (2016) 128 (22): 1921.

https://doi.org/10.1182/blood.V128.22.1921.1921

Published: 2016

Journal Articles

A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma

Jonathon B. Cohen, MD, Jeffrey Switchenko, PhD, Jean L. Koff, MD, Rajni Sinha, MD MRCP, Jonathan L. Kaufman, MD, H. Jean Khoury, MD FACP, Nassoma K Bumpers, PA, Amanda Colbert, Amanda A Hutchison-Rzepka, BA, Loretta J. Nastoupil, MD, Leonard T. Heffner, MD, Amelia Langston, MD, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Christopher R. Flowers, MD

Blood (2014) 124 (21): 4432.

https://doi.org/10.1182/blood.V124.21.4432.4432

Published: 2014

Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Blood (2012) 120 (21): 3747.

https://doi.org/10.1182/blood.V120.21.3747.3747

Published: 2012

Journal Articles

Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia

Fuad El Rassi, MD, Martha Arellano, MD, Leonard T Heffner, MD, Edmund K. Waller, MD, PhD, Elliott F. Winton, MD, Kevin Ward, PhD, MPH, CTR, H. Jean Khoury, MD, FACP

Blood (2012) 120 (21): 4309.

https://doi.org/10.1182/blood.V120.21.4309.4309

Published: 2012

Journal Articles

Cerebrospinal Fluid Flow Cytometry in Acute Lymphoblastic Leukemia/Lymphoma: Is It Beneficial?.

Fuad El Rassi, MD, Zahi Mitri, MD, Leonard T Heffner, M.D., Amelia Langston, MD, Edmund K. Waller, MD, PhD, Elliott F. Winton, MD, Morgan L. McLemore, MD, Leon Bernal, MD, Martha Arellano, MD, H. Jean Khoury, MD, FACP

Blood (2012) 120 (21): 2576.

https://doi.org/10.1182/blood.V120.21.2576.2576

Published: 2012

Journal Articles

CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial,

Leslie S. Kean, MD, PhD, Amelia Langston, MD, Muna Qayad, MD, H. Jean Khoury, MD, FACP, Divya Tiwari, MD, Cynthia Couture, Heather Renfroe, Sharon Sen, Jennifer Robertson, PhD, Edmund K Waller, MD PhD, John T. Horan

Blood (2011) 118 (21): 4078.

https://doi.org/10.1182/blood.V118.21.4078.4078

Published: 2011

Journal Articles

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, Michael J. Mauro, MD, Stuart L. Goldberg, MD, Ron Paquette, MD, PhD, H. Jean Khoury, MD, FACP, Ishan Hirji, MPH, Samuel Wagner, PhD, RPh, Sam Joo, PhD, Catherine Davis, PharmD

Blood (2011) 118 (21): 4435.

https://doi.org/10.1182/blood.V118.21.4435.4435

Published: 2011

Journal Articles

Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes

Rami S. Komrokji, MD, Alan F. List, MD, H. Jean Khoury, MD, FACP, Jeffrey E. Lancet, MD, Elias Jabbour, Maria C Foudray, RN, Shannon L Winski, PhD, Stacie Bell, PhD, Selena Armistead Rush, BS, Lara Maloney, BA, Ann Marie Ptaszynski, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2011) 118 (21): 118.

https://doi.org/10.1182/blood.V118.21.118.118

Published: 2011

Journal Articles

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

Blood (2011) 118 (21): 109.

https://doi.org/10.1182/blood.V118.21.109.109

Published: 2011

Journal Articles

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

R. Donald Harvey, PharmD, Sagar Lonial, MD, Heather Renfroe, Rajni Sinha, MD, MRCP, Christopher R Flowers, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, FACP, Amelia Langston, MD, Edmund K Waller, MD PhD, Jonathan L. Kaufman, MD

Blood (2011) 118 (21): 2988.

https://doi.org/10.1182/blood.V118.21.2988.2988

Published: 2011

Journal Articles

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

H. Jean Khoury, MD, FACP, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, Neil P. Shah, MD, Ph.D., M. Brigid Bradley-Garelik, MD, David Dejardin, Andreas Hochhaus, MD

Blood (2010) 116 (21): 3421.

https://doi.org/10.1182/blood.V116.21.3421.3421

Published: 2010

Journal Articles

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

H. Jean Khoury, MD, FACP, Robert H. Collins, Jr, MD, William Blum, MD, Lori Maness, MD, Patrick Stiff, MD, Stephen M. Kelsey, MD, Anita Reddy, PhD, Jennifer A. Smith, PhD, John F. DiPersio, MD, PhD

Blood (2010) 116 (21): 2190.

https://doi.org/10.1182/blood.V116.21.2190.2190

Published: 2010

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, H. Jean Khoury, MD, FACP, Franck Emmanuel Nicolini, MD, PhD, Selim Corm, Jeffrey H. Lipton, MD,PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Hagop Kantarjian, MD

Blood (2009) 114 (22): 644.

https://doi.org/10.1182/blood.V114.22.644.644

Published: 2009

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Jorge Cortes, MD, Hagop M Kantarjian, Dong- Wook Kim, MD, PhD, H. Jean Khoury, MD, FACP, Anna G. Turkina, MD, Zhi-Xiang Shen, MD, Tim H Brummendorf, MD, Mammen Chandy, MD, Steven Arkin, MD, Carlo Gambacorti-Passerini, MD

Blood (2008) 112 (11): 1098.

https://doi.org/10.1182/blood.V112.11.1098.1098

Published: 2008

Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated in Patients with AP and BP CML and Ph+ ALL.

Carlo Gambacorti- Passerini, Enrico Maria Pogliani, MD, Michele Baccarani, MD, Giovanni Martinelli, Hagop M Kantarjian, Mammen Chandy, H. Jean Khoury, MD, FACP, Dong-Wook Kim, Tim H Brummendorf, Steven Arkin, MD, Jorge Cortes

Blood (2008) 112 (11): 1101.

https://doi.org/10.1182/blood.V112.11.1101.1101

Published: 2008

NARROW

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia

Cerebrospinal Fluid Flow Cytometry in Acute Lymphoblastic Leukemia/Lymphoma: Is It Beneficial?.

CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial,

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated in Patients with AP and BP CML and Ph+ ALL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only